You are here

Helsinn Healthcare SA

Member Since 2014

Riccardo Braglia, MBA

Helsinn Group Vice Chairman & Group Chief Executive Officer

Riccardo Braglia, Helsinn Group’s Vice Chairman and CEO, Managing Director and Member of Helsinn Holding’s Board of Directors, Switzerland and Executive Committee for Helsinn Group’s strategic management, has a wealth of over 30 years of international experience in the pharmaceutical industry. Mr. Braglia heads the family-run, privately owned pharmaceutical company, the Helsinn Group, founded in 1976, with a worldwide presence and focus on cancer therapeutics and supportive care.

Mr. Braglia is a Board Member of Helsinn Healthcare, Switzerland, Helsinn Advanced Synthesis, Switzerland, Helsinn Birex Pharmaceuticals, Ireland and Chairman of Helsinn Therapeutics, USA. He is also Président Directeur Général – Gérant Associé of Helsinn International Services, Monaco, Principality of Monaco and Chairman of the Helsinn Investment Fund, Luxembourg. Mr. Braglia serves as a Board Member of two portfolio companies of the Helsinn Investment Fund, QuantumDx Group Limited, UK and GreenBone Ortho S.R.L., Italy. He is also Co-founder and Board Member of Lyfebulb, USA, and a Board Member of Thorne Research, Greenwich CT/USA, Wellness-Fx and Health,  all US companies.  Mr. Braglia is a member of the Board of the Conquer Cancer Foundation, USA. Mr. Braglia is also active in the investment community as an advisor to the New York City-based venture capital firm Windham Ventures.

Riccardo Braglia holds a degree in Business Economics with a specialization in Business Industrial Management from the Luigi Bocconi University of Milan, Italy.

CEO Cancer Gold Standard™

Gold Standard  Employer

Gold Standard Employer Since 2015 | Global Gold Standard Employer Since 2015


Helsinn's mission is to bring respect, integrity, and quality to our products, services and all that we do to improve health and quality of life in every person affected by cancer. We are honored to be accredited CEO Cancer Gold Standard which means quality of life for our employees and is an additional step forward to reach our mission.

— Riccardo Braglia, MBA

Gold Standard  Task Force Participation

Task Force Member(s): Linda Burns, Executive Director, Human Resources

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member(s): Sergio Cantoreggi, PhD, Chief Scientific Officer & Global Head of R&D

Further Support

The CEO Cancer Gold Standard was featured at Helsinn's 40th Anniversary Celebration during the JP Morgan annual conference, Janurary 2016

Founding Member, CEO Roundtable on Cancer - China

Helsinn Healthcare SA

The Helsinn Group is one of the world’s leading supportive cancer care companies. Our business model is built on forging lasting alliances with worldwide partners who share our vision. Through a mix of integrated early and late stage licensing programs and our own development, we have developed a comprehensive portfolio of effective pharmaceuticals and specialist therapies that are sold in over 90 countries, and a late stage pipeline of future cancer therapies which will meet unmet medical needs in the treatment of cancer.